Sichenzia Ross Friedman Ference LLP Represents Amarantus BioScience Holdings, Inc. in a $3 Million Registered Direct Offering
February 24, 2016 – New York, NY – Press Release – Sichenzia Ross Friedman Ference LLP announced today that the Firm represented Amarantus BioScience Holdings, Inc. in a $3 million offering of the Company’s Series H Convertible Preferred Stock and Warrants to purchase common stock.
Chardan Capital Markets, LLC acted as sole placement agent for the transaction.
The securities were offered pursuant to an effective shelf registration statement.
The Sichenzia Ross Friedman Ference LLP team was led by Partners Jeffrey Fessler and Marcelle Balcombe.
Visit SRFK's LinkedIn page
Latest posts by Sichenzia Ross Ference Kesner LLP (see all)
- Founding Partner Marc Ross Speaks at Benzinga Cannabis Capital Conference - August 15, 2018
- Founding Partner Gregory Sichenzia Featured in the Media Discussing Scrutiny of Elon Musk’s Twitter Communications - August 15, 2018
- Founding Partner Gregory Sichenzia Featured on Business Insider Discussing Elon Musk’s Tweets and Securities Legality - August 8, 2018